Richiardi, L; Corbin, M; Marron, M et al.
Occupation and risk of upper aerodigestive tract cancer: The ARCAGE studyINTERNATIONAL JOURNAL OF CANCER. Bd. 130. H. 10. 2012 S. 2397-2406
Busse, W; Buhl, R; Vidaurre, CF et al.
Omalizumab and the risk of malignancy: Results from a pooled analysisJOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY. Bd. 129. H. 4. 2012 S. 983-U482
Wittchen, HU; Muhlig, S; Klotsche, J et al.
Omalizumab versus 'Usual Care': Results from a Naturalistic Longitudinal Study in Routine CareINTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY. Bd. 159. H. 1. 2012 S. 83-93
Velikova, G; Coens, C; Efficace, F et al.
on behalf of the EORTC Quality of Life Group. Health-Related Quality of Life in EORTC clinical trials - 30 years of progress from methodological developments to making a real impact on oncology practiceEuropean Journal of Cancer Supplements. Bd. 10. H. 1. 2012 S. 141-9
Wellek, S; Blettner, M
On the Proper Use of the Crossover Design in Clinical Trials Part 18 of a Series on Evaluation of Scientific PublicationsDEUTSCHES ARZTEBLATT INTERNATIONAL. Bd. 109. H. 15. 2012 S. 276-281
zu Eulenburg, P; Müller-Forell, W; Dieterich, M
On the recall of vestibular sensations2012
Frees, S; Knochlein, L; Ziesel, C et al.
ONCOLOGICAL LONG-TERM OUTCOME OF PATIENTS PRESENTING WITH CHROMOPHOBE, PAPILLARY AND CLEAR-CELL RENAL CELL CARCINOMAJOURNAL OF UROLOGY. Bd. 187. H. 4. 2012 S. E582-E583
Miederer, Matthias; Reber, Helmut; Helisch, Andreas et al.
One Single-Time-Point Kidney Uptake From OctreoScan Correlates With Number of Desintegrations Measured Over 72 Hours and Calculated for the 6.7 Hours Half-Life Nuclide Lu-177CLINICAL NUCLEAR MEDICINE. Bd. 37. H. 10. 2012 S. E245-E248
Kalkum, G; Beck, M; Larroque, S et al.
OPHTHALMOLOGICAL MANIFESTATIONS IN CHILDREN WITH FABRY DISEASE IN THE FABRY OUTCOME SURVEYJOURNAL OF INHERITED METABOLIC DISEASE. Bd. 35. 2012 S. S94-S94